HRTX News and Press, Heron Therapeutics Inc. From 06/29/20

Heron Therapeutics (NASDAQ: HRTX) , a commercial-stage biopharma company, is having a tough go of it today. The company's shares were down by 28.6% as of 10:21 a.m. EDT on Monday.  The culprit? Ahead of the opening bell, Heron announced that the Food and Drug Administration rejected its...

Heron Therapeutics (NASDAQ: HRTX ) is down  11%  premarkket in reaction to its announcement that it received a Complete Response Letter (CRL) from the FDA regarding its NDA for HTX-011 for the management of postoperative pain. More news on: Heron Therapeutics, Inc., Healthcare ...

SAN DIEGO , June 29, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it ...

Intercept Pharmaceuticals (NASDAQ: ICPT )  -38%  on FDA rejection of obeticholic acid in NASH. More news on: Intercept Pharmaceuticals, Inc., Cleveland BioLabs, Inc., China Jo-Jo Drugstores, Inc., Stocks on the move, , Read more ...

MDC Partners (NASDAQ: MDCA ) +169%  on potential business combination with Stagwell. More news on: MDC Partners Inc., Vaxart, Inc., iBio, Inc., Stocks on the move, , Read more ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

A central theme of the 2020 investing landscape has been the overall strength of healthcare stocks. Investors have gravitated toward the healthcare sector this year due to the ability of most top companies to generate healthy free cash flows, as well as their tie-in to the development of a possi...

Heron Reports Positive Results From Mid-Stage Knee Replacement Trial Heron Therapeutics (HRTX) announced that its Phase 2b clinical trial Study 209 has provided positive data with regard to HTX-011. The trial involved testing the drug candidate on patients undergoing total knee arthropla...

Heron Therapeutics ( HRTX -0.1% ) announces the publication of results, online in the Journal of Arthroplasty , from a Phase 2b clinical trial, Study 209 , evaluating HTX-011 for postoperative pain relief in patients who have undergone total knee arthroplasty (knee replacement). More...

SAN DIEGO , June 4, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that...